Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy

BACKGROUND: Biosimilars of filgrastim are in widespread clinical use in Europe. This phase III study compares biosimilar filgrastim (EP2006), with the US-licensed reference product, Neupogen(®), in breast cancer patients receiving (neo)adjuvant myelosuppressive chemotherapy (TAC). PATIENTS AND METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Blackwell, K., Semiglazov, V., Krasnozhon, D., Davidenko, I., Nelyubina, L., Nakov, R., Stiegler, G., Singh, P., Schwebig, A., Kramer, S., Harbeck, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551159/
https://www.ncbi.nlm.nih.gov/pubmed/26122726
http://dx.doi.org/10.1093/annonc/mdv281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551159/
https://www.ncbi.nlm.nih.gov/pubmed/26122726
http://dx.doi.org/10.1093/annonc/mdv281

Ejemplares similares